Rituximab treatment for multiple sclerosis linked to increased bowel disease risk

A large population-based study led by Karolinska Institutet and published in JAMA Neurology found that people with multiple sclerosis treated with rituximab have an increased risk of developing inflammatory bowel disease, especially Crohn's disease. Despite this association, the absolute risk for patients remains low. This study is the first of its kind to explore this link on a large scale.

Originally published by gnews